Register study of the Molecular Tumor Board (tumor entity-spanning molecular characterization program to evaluate individualized tumor biology-guided therapy in adults with rare and advanced tumor entities)

Register study of the Molecular Tumor Board (tumor entity-spanning molecular characterization program to evaluate individualized tumor biology-guided therapy in adults with rare and advanced tumor entities) - MTB-FR

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00025847

Enrollment

1000

Registered

2021-07-14

Start date

2020-10-08

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cross-tumor entity (adult patients = 18 years of age with any advanced tumor disease or with rare tumor entity (incidence of less than one case per 100,000 population)).

Interventions

Group 1: In the course of the Molecular Tumor Board (MTB) register study, the medical history and previous medical findings of the study participants are presented in a 2-weekly interdisciplinary conf

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. adult patients = 18 years of age with any advanced tumor disease or with rare tumor entity (incidence of less than one case per 100,000 population) 2. there are no curative or inadequate treatment options available 3. the expected life expectancy of the patient should be above 6 months 4. sufficient tumor tissue available for a backup sample that can be used for future diagnostic studies

Exclusion criteria

Exclusion criteria: 1. lack of capacity to give consent or lack of informed consent for the registry study 2. lack of a suitable tumor biopsy or too little tissue available for a reserve sample

Design outcomes

Primary

Measure	Time frame
The procedures established in the MTB-FR program are intended to: 1. document and record the analysis and treatment of Molecular Tumor Board patients 2. acceleration and interpretation of molecular data in the clinical setting 3. evaluate the utility of a genomics-based approach to targeted tumor therapy 4. to identify the frequencies of previously undescribed tumor genetic alterations within and across tumor entities, paving the way for further clinical trials in patients with comparable tumor genomes 5. to evaluate alternative molecular techniques to classify patients into risk and therapeutic groups	—

Measure

Time frame

The procedures established in the MTB-FR program are intended to: 1. document and record the analysis and treatment of Molecular Tumor Board patients 2. acceleration and interpretation of molecular data in the clinical setting 3. evaluate the utility of a genomics-based approach to targeted tumor therapy 4. to identify the frequencies of previously undescribed tumor genetic alterations within and across tumor entities, paving the way for further clinical trials in patients with comparable tumor genomes 5. to evaluate alternative molecular techniques to classify patients into risk and therapeutic groups

—

Secondary

Measure	Time frame
please refer to primary endpoint	—

Countries

Germany

Contacts

Public ContactAnna-Lena Illert

Universitätsklinikum Freiburg Klinik für Innere Medizin I Schwerpunkt Hämatologie, Onkologie und Stammzelltransplantation

Lena.Illert@uniklinik-freiburg.de0761-270-32888/32880

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026